Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase I/II pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II. Homology Medicines, Inc. was incorporated in 2015 and is based in Bedford, Massachusetts.
IPO Year: 2018
Exchange: NASDAQ
Website: homologymedicines.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/28/2023 | $9.00 → $1.50 | Outperform → Neutral | Robert W. Baird |
| 2/28/2022 | $30.00 → $20.00 | Buy | HC Wainwright & Co. |
| 2/22/2022 | $25.00 → $9.00 | Buy | B of A Securities |
| 2/22/2022 | $35.00 → $29.00 | Neutral | BTIG Research |
| 2/22/2022 | Outperform → Sector Perform | RBC Capital Mkts | |
| 2/22/2022 | $25.00 → $15.00 | Buy | Chardan Capital |
| 2/22/2022 | $35.00 → $29.00 | Buy | BTIG |
| 2/22/2022 | $30.00 → $4.00 | Outperform → Sector Perform | RBC Capital |
| 2/22/2022 | Outperform → Perform | Oppenheimer | |
| 11/16/2021 | $30.00 → $25.00 | Buy | Chardan Capital |
424B3 - Q32 Bio Inc. (0001661998) (Filer)
10-Q - Q32 Bio Inc. (0001661998) (Filer)
8-K - Q32 Bio Inc. (0001661998) (Filer)
EFFECT - Q32 Bio Inc. (0001661998) (Filer)
424B3 - Q32 Bio Inc. (0001661998) (Filer)
S-1 - Q32 Bio Inc. (0001661998) (Filer)
10-K/A - Q32 Bio Inc. (0001661998) (Filer)
8-K - Q32 Bio Inc. (0001661998) (Filer)
8-K/A - Homology Medicines, Inc. (0001661998) (Filer)
8-K - Homology Medicines, Inc. (0001661998) (Filer)
Robert W. Baird downgraded Homology Medicines from Outperform to Neutral and set a new price target of $1.50 from $9.00 previously
HC Wainwright & Co. reiterated coverage of Homology Medicines with a rating of Buy and set a new price target of $20.00 from $30.00 previously
B of A Securities reiterated coverage of Homology Medicines with a rating of Buy and set a new price target of $9.00 from $25.00 previously
BTIG Research reiterated coverage of Homology Medicines with a rating of Neutral and set a new price target of $29.00 from $35.00 previously
RBC Capital Mkts downgraded Homology Medicines from Outperform to Sector Perform
Chardan Capital reiterated coverage of Homology Medicines with a rating of Buy and set a new price target of $15.00 from $25.00 previously
BTIG reiterated coverage of Homology Medicines with a rating of Buy and set a new price target of $29.00 from $35.00 previously
RBC Capital downgraded Homology Medicines from Outperform to Sector Perform and set a new price target of $4.00 from $30.00 previously
Oppenheimer downgraded Homology Medicines from Outperform to Perform
Chardan Capital reiterated coverage of Homology Medicines with a rating of Buy and set a new price target of $25.00 from $30.00 previously
4 - Q32 Bio Inc. (0001661998) (Issuer)
4 - Q32 Bio Inc. (0001661998) (Issuer)
4 - Q32 Bio Inc. (0001661998) (Issuer)
4 - Q32 Bio Inc. (0001661998) (Issuer)
4 - Q32 Bio Inc. (0001661998) (Issuer)
4 - Q32 Bio Inc. (0001661998) (Issuer)
4 - Q32 Bio Inc. (0001661998) (Issuer)
4 - Q32 Bio Inc. (0001661998) (Issuer)
4 - Q32 Bio Inc. (0001661998) (Issuer)
4 - Q32 Bio Inc. (0001661998) (Issuer)
- ASGCT President and Entrepreneur Takes Leadership Role on SAB as Company Expects to Have Three Clinical Programs in 2021 - BEDFORD, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a clinical-stage genetic medicines company, announced today the appointment of gene therapy expert Beverly Davidson, Ph.D., as Chair of the Company's Scientific Advisory Board, on which she has served since 2018. Dr. Davidson is the Director of the Raymond G. Perelman Center for Cellular and Molecular Therapeutics, the Chief Scientific Strategy Officer, and holds the Arthur V. Meigs Chair in Pediatrics at the Children's Hospital of Philadelphia. She was also recently named Pr
Oxford Biomedica and Homology Medicines to establish Oxford Biomedica Solutions LLC, a new U.S.-based AAV Manufacturing and Innovation Business Homology Medicines to receive $130 million from Oxford Biomedica to continue to advance its three clinical programs and genetic medicines platform Oxford Biomedica to invest $50 million to fund the growth of Oxford Biomedica Solutions LLC and will own 80%, with Homology Medicines to own 20%; Homology Medicines to secure preferred key customer status Dr. Roch Doliveux to become Interim CEO of Oxford Biomedica and John Dawson to retire as CEO and remain a Board Director of Oxford Biomedica Oxford Biomedica and Homology Medicines to host webcasts t